Clinical Trial Detail

NCT ID NCT01182350
Title Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

childhood brain stem glioma

Therapies

Bevacizumab + Temozolomide

Bevacizumab + Erlotinib + Temozolomide

Bevacizumab + Erlotinib

Bevacizumab

Age Groups: child

No variant requirements are available.